The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer

Genitourinary Cancer

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

Expert Rev Clin Pharmacol.

Vogelzang NJ

doi: 10.1080/

Genitourinary Cancer

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Eur J Cancer.

Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE

doi: 10.1016/j.ejca.2016.10.020.

Genitourinary Cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging.

Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, Nitzsche E, Sundram F, Vogel W, Oyen W, Lewington V

doi: 10.1007/s00259-017-3756-7.

Genitourinary Cancer

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

Eur J Cancer.

van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N

doi: 10.1016/j.ejca.2020.05.001.

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Prostate.

Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C

doi: 10.1002/pros.23180.

SPECIAL REPORT

Genitourinary Cancer

Traitement ciblé par le radium-223, émetteur de particules alpha, dans le cancer de la prostate avec métastases osseuses

Genitourinary Cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Lancet Oncol.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators

doi: 10.1016/

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Clin Genitourin Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S

doi: 10.1016/j.clgc.2017.08.020.

RECOMMENDED

Genitourinary Cancer

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C

Related content

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Traitement ciblé par le radium-223, émetteur de particules alpha, dans le cancer de la prostate avec métastases osseuses

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial